UBS Maintains Buy on Amgen, Raises Price Target to $470

UBS analyst Michael Yee has maintained a Buy rating on Amgen (NASDAQ: AMGN) and increased the price target from $430 to $470. This adjustment reflects a positive outlook on the company's performance.